Irritable bowel syndrome: focus on otilonium bromide

被引：9

作者：

Boeckxstaens, Guy ^{[1
]}

Clave, Pere ^{[2
,3
]}

Corazziari, Enrico S. ^{[4
]}

Tack, Jan ^{[1
,5
]}

机构：

[1] Univ Leuven, Dept Gastroenterol, Leuven, Belgium

[2] Univ Autonoma Barcelona, Dept Surg, Hosp Mataro, E-08193 Barcelona, Spain

[3] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain

[4] Univ Roma La Sapienza, UOC Gastroenterol A, Dipartimento Med Interna & Specialita Med, Rome, Italy

[5] Univ Leuven, Translat Res Ctr Gastrointestinal Disorders TARGI, B-3000 Leuven, Belgium

来源：

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY | 2014年 / 8卷 / 02期

关键词：

bromide; impact on daily life; irritable bowel syndrome; otilonium; spasmolytics; treatment; EUROPEAN PERSPECTIVE; NK2; RECEPTOR; DOUBLE-BLIND; PREVALENCE; PATTERNS; IMPACT; COLON; SENSITIVITY; EFFICACY; 15-WEEK;

D O I：

10.1586/17474124.2014.869477

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Irritable bowel syndrome is a prevalent and chronic disorder, characterized by recurrent abdominal pain/discomfort, bloating and altered bowel habits. This condition affects an estimated 10-15% of the population worldwide and impacts heavily on a patient's daily life and ability to work, as well as healthcare resource utilization. Drug therapy aimed at correcting the primary symptoms of diarrhea/constipation/bloating may have little effect on abdominal pain, which results from visceral hypersensitivity. Smooth muscle relaxants or antispasmodics decrease the tone and contractility of intestinal smooth muscle, effectively managing abdominal pain. Otilonium bromide has been widely used worldwide and has been found to be safe and well tolerated, and superior to placebo for the reduction of symptoms and the prevention of symptom relapse in patients with irritable bowel syndrome.

引用

页码：131 / 137

页数：7

共 31 条

[1] Irritable bowel syndrome - Recent and novel therapeutic approaches [J].